Robert Azelby - 31 Oct 2022 Form 4 Insider Report for Eliem Therapeutics, Inc. (CLYM)

Role
President & CEO, Director
Signature
/s/ Alan Hambelton, Attorney-in-Fact
Issuer symbol
CLYM
Transactions as of
31 Oct 2022
Net transactions value
$0
Form type
4
Filing time
02 Nov 2022, 19:09:49 UTC
Previous filing
31 Jan 2022
Next filing
12 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELYM Stock Option (Right to Buy) Award $0 +500,000 $0.000000 500,000 31 Oct 2022 Common Stock 500,000 $3.27 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the "2022 Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2022 Vesting Commencement Date.